PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. (PROSTAC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02362620 |
|
Recruitment Status : Unknown
Verified January 2020 by Centro Nacional de Investigaciones Oncologicas CARLOS III.
Recruitment status was: Active, not recruiting
First Posted : February 13, 2015
Last Update Posted : January 27, 2020
|
Sponsor:
Centro Nacional de Investigaciones Oncologicas CARLOS III
Information provided by (Responsible Party):
Centro Nacional de Investigaciones Oncologicas CARLOS III
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Actual Primary Completion Date : | April 2018 |
| Estimated Study Completion Date : | December 2020 |